Stock info Stratec | Filter  Basic-Info

Stratec

Stratec's core business is the pharmaceutical sector. The global pharmaceutical companies gained around 75 percent worldwide over the last 10 years. Since 2011 the sector is 147 percent higher and over the past year minus 75 percent.

The past year gave good returns for Stratec investors

Over the last 12 months, that were loss-making period for the investors in Stratec, the stock lost around 20 percent. Over the past 5 years Stratec' stock rose at around 45 percent in value. Stratec's revenues between 2011 and 2015 were relatively steady and moved between 122,6 million euros and 146,88 million euros. During 2011 and 2015 Stratec's net results were very volatile and fluctuated between 15,75 million euros and 22,08 million euros.

Over the past 5 years the German company paid out dividends. Stratec's dividend return over the period 2011 - 2015 was around 3,16 percent per year.

At the end of 2015 the company had around 544 people employed.

Quite a lot of debt Stratec

At the end of 2015 the German company had a balance sheet of 158,93 million euros. Last year the total debt of the company was 28,65 million euros. This equals around 18,03 percent of the total balance sheet. The German company's price/earnings-ratio was 25. So the market valued the stock at 25 times the 2015' earnings per share. Based on it's price/earnings-ratio and dividend yield the German stock can be seen as a value stock.

At the end of 2015 the pharmaceutical company's market capitalization (the number of shares times the market price) equaled around 720,43 million euros. At the end of 2015 around 11,81 million stocks were listed.

On this page you can find all Stratec's financial reports. More information about Stratec can be found it's website. .